Skip to main navigation
Skip to search
Skip to main content
Johns Hopkins University Home
Home
Profiles
Research units
Research output
Search by expertise, name or affiliation
Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection
UNITY-1 Study Group
School of Medicine
Research output
:
Contribution to journal
›
Article
›
peer-review
89
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine & Life Sciences
8-cyclohexyl-N-((dimethylamino)sulfonyl)-1,1a,2,12b-tetrahydro-11-methoxy-1a-((3-methyl-3,8-diazabicyclo(3.2.1)oct-8-yl)carbonyl)cycloprop(d)indolo(2,1-a)(2)benzazepine-5-carboxamide
100%
asunaprevir
84%
Hepacivirus
46%
Genotype
35%
Infections
23%
Chronic Hepatitis C
12%
Therapeutics
8%
Antiviral Agents
6%
Sustained Virologic Response
5%
Ribavirin
4%
Drug Combinations
3%
Protease Inhibitors
3%
Alanine Transaminase
3%
France
3%
Canada
3%
Nausea
3%
Fatigue
3%
Diarrhea
3%
Fibrosis
2%
Virus Diseases
2%
RNA
2%
Health Care Outcome Assessment
2%